Viewing Study NCT00136604

Home Icon Home Search Icon Search Certify Doc Icon Certify Doc Certify Doc Icon Genes Certify Doc Icon Clinical Trials Certify Doc Icon CompTox Processes Icon DrugMatrix Open Targets Icon Open Targets Processes Icon Products Support Icon Support Bugs Icon Bugs
Main Search Make This Study a Gene Therapy Make This Study a Not Gene Therapy Report Bug
Ignite Creation Date: 2025-12-24 @ 9:11 PM
Ignite Modification Date: 2026-03-18 @ 12:30 AM
Study NCT ID: NCT00136604
Status: COMPLETED
Last Update Posted: 2020-02-20
First Post: 2005-08-26
Is Gene Therapy: True
Has Adverse Events: True
Brief Title: Response to GSK Biologicals' Tritanrix-HepB/Hib-MenAC Vacc (4th Dose) at 15-24m & Mencevax ACWY at 24-30m
Sponsor: GlaxoSmithKline
Organization:
Overview Dates Organization Conditions Design Enrollment Locations Outcomes Modules Raw JSON

Conditions & Keywords Data

Conditions:

Conditions

Condition Brief Condition Text View
None Whole Cell Pertussis View
None Haemophilus Influenzae Type b View
None Hepatitis B View
None Diphtheria View
None Tetanus View
None Diphtheria-Tetanus-Pertussis-Hepatitis B-Haemophilus Influenzae Type b-Neisseria Meningitidis Vaccin View
Keywords:

Keywords

Keyword Brief Keyword Text View
None Prophylaxis diphtheria View
None Hib & meningococcal serogroup A & C disease View